| Name | Title | Contact Details |
|---|
Biography Identity is a Bellingham, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
MSU Health Care is the multi-specialty medical practice of Michigan State University, with approximately 300 physicians, nurse practitioners and physician assistants. Our providers are university researchers and academic professors, spanning 25 adult and pediatric specialties. Our commitment to education allows our providers to teach future medical professionals and participate in research. Our large clinical practice connects you to the latest medical advancements, including opportunities to participate in clinical trials. Our providers practice at office locations throughout the greater Lansing area and serve patients from Mid-Michigan, and beyond. The largest clinical practice location is the MSU Clinical Center, situated on the MSU campus in East Lansing. Our locations offer multiple primary and specialty services, as well as a pharmacy, laboratory and radiology services. Our providers also treat patients at McLaren Greater Lansing and Sparrow Hospitals, in addition to several outlying community hospitals, nursing homes, rehabilitation centers, wound care centers, and Ingham County Health Department clinics.
Enochian BioSciences (formerly DanDrit Biotech USA Inc.) a biopharmaceutical company, focuses on the development and commercialization of novel therapies aimed to change the course of immunotherapy treatments for HIV/AIDS and cancer.
WebMD is a leading provider of health information services to consumers, physicians, healthcare professionals, employers and health plans.
Kolltan Pharmaceuticals is a private company founded in 2007 that is developing novel monoclonal antibody (mAb) drugs targeting receptor tyrosine kinases (RTKs). Kolltan's primary targets derive from seminal discoveries made in the laboratory of Dr. Joseph Schlessinger, Chairman of the Department of Pharmacology at the Yale School of Medicine, and in Kolltan’s laboratories. Dr. Schlessinger's laboratory has characterized a novel molecular mechanism underlying activation of RTKs providing, for the first time, a clear molecular explanation — at atomic resolution — for the oncogenic activity of mutations that have been identified in a variety of human cancers.